Coverage Initiated on ‘One of the Most Undervalued Biotech Companies in Canada’

Source: Streetwise Reports   12/06/2017 David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. In a Nov. 15, 2017, research report, Beacon Securities . . . → Read More: Coverage Initiated on ‘One of the Most Undervalued Biotech Companies in Canada’ Similar Articles: Coverage Initiated on Solar Power Firm with ‘Strong Backlog Powering Rapid Growth’ Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an ‘Exciting, Undiscovered Story’ With Completion of Offer, Analyst Says This Biotech Stock Could Triple